Silexion Therapeutics, Evonik collaborate on siRNA formulation development

Silexion Therapeutics (SLXN) revealed its ongoing collaboration with Evonik for the development of an advanced siRNA formulation aimed at enhancing cancer treatment efficacy. Through this existing collaboration, Evonik’s proprietary biodegradable long-acting PLGA microparticle formulation was used for SIL-204, Silexion’s next-generation siRNA candidate. This innovative formulation has demonstrated high efficacy in preclinical models using mice with human pancreatic tumor cell lines carrying various KRAS mutations. By leveraging Evonik’s formulation expertise, Silexion aims to deliver sustained-release RNAi therapy, allowing for more effective targeting of KRAS mutations-one of the most challenging genetic drivers in oncology.